-

Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster

First-of-its-kind bench scale bioreactor enabling productivity, scalability and efficiency supporting reduced environmental impact

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the 5L DynaDrive Single-Use Bioreactor (S.U.B.), designed to meet the evolving needs of modern bioprocessing. The 5L DynaDrive expands the company's robust portfolio of bioreactors, offering seamless scalability from 1 to 5,000 liters and accelerating bench-scale process development, while facilitating the cost-effective transition from bench to commercialization with consistent reactor design and film across all scales.

"The introduction of the 5L DynaDrive marks a significant advancement in our commitment to helping customers maximize productivity and accelerate time to market," said Ray Mercier, president of Thermo Fisher’s single-use technologies business. "With 25 years of experience in single-use technology, we are dedicated to meeting our customers' evolving needs. Our trusted innovations provide seamless scalability and enhanced efficiency, enabling customers to streamline their bioprocessing workflows and successfully develop and commercialize life-saving therapies."

The 5L DynaDrive single-use bioreactor is engineered to meet the diverse needs of large biopharma, Contract Development and Manufacturing Organizations (CDMOs), and small biotech companies. Its user-friendly design and benchtop size enables use with the HyPerforma™ G3Lab Controller to provide exceptional scalability and scalable proof of concept, affordably. With a 27% increase in productivity compared to glass bioreactors, the 5L DynaDrive combines small size with high performance and offers effective scale-up with consistent design, software, and film across all sizes. The robust, reliable solution utilizes biobased films built on Thermo Fisher’s existing Aegis™ film offerings and BioTitan Retention Devices, enabling minimized product loss and more sustainability.

To learn more about Thermo Fisher’s DynaDrive portfolio, please visit www.thermofisher.com/dynadrive.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher’s presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinic...

Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample traceability. Food testing laboratories face growing pressure to process more samples, meet turnaround expectations and maintain consistent quality while managing staffing constraints, sustainability goals and inc...

Thermo Fisher Scientific Reports Second Quarter 2026 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026. Second Quarter Highlights Second quarter revenue grew 10% to $11.99 billion Second quarter GAAP diluted earnings per share (EPS) grew 9% to $4.68 Second quarter adjusted EPS grew 13% to $6.03 “We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strateg...
Back to Newsroom